Axonics Modulation Technologies (NASDAQ:AXNX) will release its earnings data after the market closes on Monday, August 5th. Analysts expect Axonics Modulation Technologies to post earnings of ($0.51) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
Axonics Modulation Technologies (NASDAQ:AXNX) last released its earnings results on Wednesday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.07). The firm had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.53 million. On average, analysts expect Axonics Modulation Technologies to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
AXNX stock opened at $36.11 on Friday. The company has a market capitalization of $1.03 billion and a price-to-earnings ratio of -7.78. The company has a current ratio of 22.83, a quick ratio of 22.07 and a debt-to-equity ratio of 0.16. The firm has a 50 day simple moving average of $38.36. Axonics Modulation Technologies has a 12-month low of $11.95 and a 12-month high of $43.37.
In other news, Director Nancy Lynn Md Snyderman acquired 2,000 shares of Axonics Modulation Technologies stock in a transaction on Thursday, June 27th. The stock was acquired at an average cost of $37.12 per share, with a total value of $74,240.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Rinda Sama sold 13,345 shares of the stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $28.03, for a total value of $374,060.35. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,040 shares of company stock valued at $832,724. 35.99% of the stock is owned by corporate insiders.
Several research firms have recently issued reports on AXNX. Zacks Investment Research lowered Axonics Modulation Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, July 3rd. Wells Fargo & Co upped their target price on Axonics Modulation Technologies from $35.00 to $47.00 and gave the company an “outperform” rating in a report on Tuesday, July 2nd. SunTrust Banks upped their target price on Axonics Modulation Technologies to $33.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Bank of America increased their price objective on Axonics Modulation Technologies from $30.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $30.78.
About Axonics Modulation Technologies
Axonics Modulation Technologies, Inc, a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention.
Featured Article: Different Types of Derivatives
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.